Copyright
©The Author(s) 2016.
World J Stem Cells. Mar 26, 2016; 8(3): 106-117
Published online Mar 26, 2016. doi: 10.4252/wjsc.v8.i3.106
Published online Mar 26, 2016. doi: 10.4252/wjsc.v8.i3.106
Table 1 Effect of treatment with bone marrow derived mesenchymal stem cells on serum transforming growth factor beta-1 and monocyte chemoattractant protein-1 levels in Parkinson’s disease model
Table 2 Effect of treatment with bone marrow derived mesenchymal stem cells on serum brain derived neurotrophic factor and brain dopamine levels as well as brain tyrosine hydroxylase and nestin genes expression level in Parkinson’s disease model
BDNF (pg/mL) | DA (μg/g tissue) | Relative expression of TH gene (TH/β-actin) | Relative expression of nestin gene (nestin/β-actin) | |
Ovariectomized control | 3700 ± 26.4 | 882 ± 20.3 | 1.19 ± 0.004 | 1.30 ± 0.004 |
PD untreated | 2905 ± 72.9a | 599 ± 9.8a | 0.54 ± 0.009a | 0.67 ± 0.006a |
PD + BM-MSCs | 3663 ± 17.8c | 874 ± 15.0c | 1.18 ± 0.004c | 1.29 ± 0.005c |
Table 3 Effect of treatment with bone marrow derived mesenchymal stem cells on brain survivin expression in Parkinson’s disease model
Survivin (cell number) | |
Ovariectomized control | 288 ± 16.5 |
PD untreated | 271.5 ± 13.9 |
PD + BM-MSCs | 293.2 ± 15.9 |
- Citation: Ahmed HH, Salem AM, Atta HM, Eskandar EF, Farrag ARH, Ghazy MA, Salem NA, Aglan HA. Updates in the pathophysiological mechanisms of Parkinson’s disease: Emerging role of bone marrow mesenchymal stem cells. World J Stem Cells 2016; 8(3): 106-117
- URL: https://www.wjgnet.com/1948-0210/full/v8/i3/106.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v8.i3.106